GB2589049C - Anti-IgE antibodies - Google Patents

Anti-IgE antibodies Download PDF

Info

Publication number
GB2589049C
GB2589049C GB1905150.7A GB201905150A GB2589049C GB 2589049 C GB2589049 C GB 2589049C GB 201905150 A GB201905150 A GB 201905150A GB 2589049 C GB2589049 C GB 2589049C
Authority
GB
United Kingdom
Prior art keywords
ige antibodies
ige
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1905150.7A
Other languages
English (en)
Other versions
GB2589049B (en
GB201905150D0 (en
GB2589049A (en
Inventor
Saunders Michael
Bigirimana Rene
Blanchetot Christophe
Cromheecke Marijn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Priority to GB1905150.7A priority Critical patent/GB2589049C/en
Publication of GB201905150D0 publication Critical patent/GB201905150D0/en
Priority to BR112021020329A priority patent/BR112021020329A2/pt
Priority to KR1020217034261A priority patent/KR20210150430A/ko
Priority to PCT/EP2020/060240 priority patent/WO2020208177A1/en
Priority to EA202192785A priority patent/EA202192785A1/ru
Priority to US17/598,033 priority patent/US20220177604A1/en
Priority to PH1/2021/552545A priority patent/PH12021552545A1/en
Priority to CA3133941A priority patent/CA3133941A1/en
Priority to EP20718649.5A priority patent/EP3953396A1/en
Priority to MX2021012457A priority patent/MX2021012457A/es
Priority to JP2021559827A priority patent/JP7586833B2/ja
Priority to AU2020271405A priority patent/AU2020271405A1/en
Priority to CN202080038130.8A priority patent/CN113939540A/zh
Priority to MA055600A priority patent/MA55600A/fr
Priority to SG11202110247XA priority patent/SG11202110247XA/en
Publication of GB2589049A publication Critical patent/GB2589049A/en
Priority to IL287035A priority patent/IL287035A/en
Publication of GB2589049B publication Critical patent/GB2589049B/en
Application granted granted Critical
Publication of GB2589049C publication Critical patent/GB2589049C/en
Priority to US19/257,976 priority patent/US20250388699A1/en
Priority to US19/258,059 priority patent/US20250388700A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB1905150.7A 2019-04-11 2019-04-11 Anti-IgE antibodies Active GB2589049C (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GB1905150.7A GB2589049C (en) 2019-04-11 2019-04-11 Anti-IgE antibodies
JP2021559827A JP7586833B2 (ja) 2019-04-11 2020-04-09 抗IgE抗体
CN202080038130.8A CN113939540A (zh) 2019-04-11 2020-04-09 抗IgE抗体
PCT/EP2020/060240 WO2020208177A1 (en) 2019-04-11 2020-04-09 ANTI-IgE ANTIBODIES
EA202192785A EA202192785A1 (ru) 2019-04-11 2020-04-09 АНТИТЕЛА К IgE
US17/598,033 US20220177604A1 (en) 2019-04-11 2020-04-09 ANTI-IgE ANTIBODIES
PH1/2021/552545A PH12021552545A1 (en) 2019-04-11 2020-04-09 ANTI-IgE ANTIBODIES
CA3133941A CA3133941A1 (en) 2019-04-11 2020-04-09 Anti-ige antibodies
EP20718649.5A EP3953396A1 (en) 2019-04-11 2020-04-09 Anti-ige antibodies
MX2021012457A MX2021012457A (es) 2019-04-11 2020-04-09 Anticuerpos anti-ige.
BR112021020329A BR112021020329A2 (pt) 2019-04-11 2020-04-09 Anticorpos anti-ige
AU2020271405A AU2020271405A1 (en) 2019-04-11 2020-04-09 Anti-IgE antibodies
KR1020217034261A KR20210150430A (ko) 2019-04-11 2020-04-09 항-IgE 항체
MA055600A MA55600A (fr) 2019-04-11 2020-04-09 Anticorps anti-ige
SG11202110247XA SG11202110247XA (en) 2019-04-11 2020-04-09 ANTI-IgE ANTIBODIES
IL287035A IL287035A (en) 2019-04-11 2021-10-06 Anti-ige antibodies
US19/257,976 US20250388699A1 (en) 2019-04-11 2025-07-02 Variant fc regions
US19/258,059 US20250388700A1 (en) 2019-04-11 2025-07-02 Variant fc regions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1905150.7A GB2589049C (en) 2019-04-11 2019-04-11 Anti-IgE antibodies

Publications (4)

Publication Number Publication Date
GB201905150D0 GB201905150D0 (en) 2019-05-29
GB2589049A GB2589049A (en) 2021-05-26
GB2589049B GB2589049B (en) 2023-12-13
GB2589049C true GB2589049C (en) 2024-02-21

Family

ID=66809886

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1905150.7A Active GB2589049C (en) 2019-04-11 2019-04-11 Anti-IgE antibodies

Country Status (16)

Country Link
US (3) US20220177604A1 (cg-RX-API-DMAC7.html)
EP (1) EP3953396A1 (cg-RX-API-DMAC7.html)
JP (1) JP7586833B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210150430A (cg-RX-API-DMAC7.html)
CN (1) CN113939540A (cg-RX-API-DMAC7.html)
AU (1) AU2020271405A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021020329A2 (cg-RX-API-DMAC7.html)
CA (1) CA3133941A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192785A1 (cg-RX-API-DMAC7.html)
GB (1) GB2589049C (cg-RX-API-DMAC7.html)
IL (1) IL287035A (cg-RX-API-DMAC7.html)
MA (1) MA55600A (cg-RX-API-DMAC7.html)
MX (1) MX2021012457A (cg-RX-API-DMAC7.html)
PH (1) PH12021552545A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110247XA (cg-RX-API-DMAC7.html)
WO (1) WO2020208177A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス, インコーポレイテッド Asgpr細胞表面受容体結合化合物及びコンジュゲート
US20260035484A1 (en) * 2021-10-29 2026-02-05 Longbio Pharma (Suzhou) Co., Ltd. Isolated antigen binding protein and use thereof
CN116262786B (zh) * 2021-12-13 2026-05-15 南京融捷康生物科技有限公司 针对folr1的单域抗体及其衍生蛋白和应用
KR20250037789A (ko) 2022-06-15 2025-03-18 아르젠엑스 비브이 Fcrn/항원-결합 분자 및 사용 방법
IL318098A (en) 2022-07-01 2025-02-01 Alk Abell? As IGE-FCER pushers
CN115724951B (zh) * 2022-11-15 2023-10-03 怡道生物科技(苏州)有限公司 与11型hpv结合的抗体或其抗原结合片段及其应用
EP4651901A1 (en) * 2023-01-18 2025-11-26 Lycia Therapeutics, Inc. Cycling lysosomal targeting antibody conjugates
CN118725128B (zh) * 2023-03-28 2025-09-16 东莞市朋志生物科技有限公司 抗IgE抗体、检测IgE的试剂和试剂盒
CN119490594B (zh) * 2023-08-15 2025-09-16 东莞市朋志生物科技有限公司 一种抗免疫球蛋白e的抗体及其应用
US20250101111A1 (en) * 2023-09-07 2025-03-27 argenx BV Fcrn antagonists and methods of use
GB202318512D0 (en) * 2023-12-04 2024-01-17 argenx BV Methods of determining potency
WO2025229206A1 (en) * 2024-05-03 2025-11-06 argenx BV Monovalent anti-iga binding molecules and methods of use
US20250353928A1 (en) 2024-05-17 2025-11-20 Excellergy, Inc. Antibodies and antibody fragments that bind ige
TW202604967A (zh) * 2024-06-07 2026-02-01 美商紐維格醫療公司 經修飾之Fc多肽
WO2026015664A1 (en) * 2024-07-10 2026-01-15 Lycia Therapeutics, Inc. Cycling lysosomal targeting chimeras targeting immunoglobulin e (ige)

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1370288B1 (en) 2000-11-20 2012-01-11 Canadian Blood Services Method for treating thrombocytopenia with monoclonal ivig
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2487932A1 (en) 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004204817C1 (en) 2003-01-13 2011-01-20 Macrogenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
WO2004070010A2 (en) 2003-02-01 2004-08-19 Tanox, Inc. A method for generating high affinity antibodies
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
TWI667346B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
CN106103476B (zh) 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
EP4241852A3 (en) * 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
MX386491B (es) 2015-03-09 2025-03-18 argenx BV Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
GB201707484D0 (en) 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies

Also Published As

Publication number Publication date
BR112021020329A2 (pt) 2021-12-14
SG11202110247XA (en) 2021-10-28
US20250388700A1 (en) 2025-12-25
JP7586833B2 (ja) 2024-11-19
GB2589049B (en) 2023-12-13
IL287035A (en) 2021-12-01
GB201905150D0 (en) 2019-05-29
MX2021012457A (es) 2022-01-04
GB2589049A (en) 2021-05-26
US20220177604A1 (en) 2022-06-09
EA202192785A1 (ru) 2022-03-03
WO2020208177A1 (en) 2020-10-15
MA55600A (fr) 2022-02-16
US20250388699A1 (en) 2025-12-25
CA3133941A1 (en) 2020-10-15
EP3953396A1 (en) 2022-02-16
JP2022528927A (ja) 2022-06-16
PH12021552545A1 (en) 2022-07-04
KR20210150430A (ko) 2021-12-10
CN113939540A (zh) 2022-01-14
AU2020271405A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
SG11202110247XA (en) ANTI-IgE ANTIBODIES
IL280780A (en) Anti-TIGIT antibodies
IL291068A (en) Anti-cd73 antibodies
IL289112A (en) Antibodies against tigit
IL280013A (en) Anti-IL36R antibodies
SG11202108141VA (en) Novel cd40-binding antibodies
IL279352A (en) IL-11RA antibodies
IL278010A (en) Antibodies to galectin 10
IL277030A (en) Antibodies
GB202110263D0 (en) Anti-btla antibodies
IL284584A (en) Anti-tigit antibodies
ZA202108836B (en) Anti-epha4 antibody
GB2581174B (en) Antibodies against hEPCR
IL288693A (en) Anti-Ige structure
GB201917480D0 (en) Antibodies
GB201900732D0 (en) Antibodies
GB201806084D0 (en) Antibodies
GB201919062D0 (en) Antibody
SG11201913540VA (en) Anti-Podoplanin Antibody
IL289160A (en) Anti-angpt2 antibodies
PL4025612T3 (pl) Przeciwciała anty-fukozylo-gm1
GB2598698B (en) Affinity-maturated anti-ASICIa antibodies
HK40060574A (en) Anti-ige antibodies
GB201919280D0 (en) Antibodies
GB201901648D0 (en) Galectin-10 antibodies

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20210603 AND 20210609

732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20230309 AND 20230315

S117 Correction of errors in patents and applications (sect. 117/patents act 1977)

Free format text: REQUEST FILED; REQUEST FOR CORRECTION UNDER SECTION 117 FILED ON 24 NOVEMBER 2023

S117 Correction of errors in patents and applications (sect. 117/patents act 1977)

Free format text: CORRECTIONS ALLOWED; REQUEST FOR CORRECTION UNDER SECTION 117 FILED ON 24 NOVEMBER 2023 WAS ALLOWED ON 05 FEBRUARY 2024